Beta-blockers in asthma

Australia has one of the highest prevalence rates for asthma in the world, affecting around 15% of the population. Short-acting beta₂ agonists (SABAs) have a longstanding role as the main treatment option for the acute relief of symptoms, while more recently long-acting beta₂ agonists (LABAs) have been recommended for use as add-on therapy to inhaled corticosteroids for the prevention of symptoms.